Everything below concerns Phase 3 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
== Epidemiology == While episcleritis is a common disease, its exact prevalence and incidence are unknown. It typically affects young or middle aged women. The diffuse form of episcleritis (70%) is more common than the nodular form (30%). One retrospective study found 28 percent of individuals with episcleritis experienced recurrent episodes of the disease.
The Terciopelo (Bothrops asper) has been described as excitable and unpredictable when disturbed. They can, and often will, move very quickly, usually opting to flee from danger, but can suddenly reverse direction to vigorously defend themselves. Adult specimens, when cornered and fully alert, should be considered dangerous. In a review of bites from this species suffered by field biologists, Hardy (1994) referred to it as the "ultimate pit viper". Venom yield (dry weight) averages 458 mg, with a maximum of 1530 mg (Bolaños, 1984) and an LD50 in mice of 2.844 mg/kg IP. This species is an important cause of snakebite within its range. It is considered the most dangerous snake in Costa Rica, responsible for 46% of all bites and 30% of all hospitalized cases; before 1947, the fatality rate was 7%, but this has since declined to almost 0% (Bolaños, 1984), mostly due to the Clodomiro Picado Research Institute, responsible for the production of antivenom. In the Colombian states of Antioquia and Chocó, it causes 50–70% of all snakebites, with a sequelae rate of 6% and a fatality rate of 5% (Otero et al., 1992). In the state of Lara, Venezuela, it is responsible for 78% of all envenomations and all snakebite fatalities. One of the reasons so many people are bitten is its association with human habitation, and many bites occur indoors.
Penn Station is configured with 11 platforms, 21 tracks, and four interlockings. The station's platforms and tracks are numbered from south to north. Tracks 1–4 are stub-end tracks ending at the eastern end of the platform and are used exclusively by NJ Transit, as they do not connect to the East River Tunnels. The remaining tracks 5 through 21 are through tracks with connections at both ends. In normal operations, Amtrak and NJ Transit share tracks 5–12, all three railroads share tracks 13–16, and the LIRR has the exclusive use of tracks 17–21 on the north side of the station. The station is accessed via seven single-track tunnels: two North River Tunnels under the Hudson River, four East River Tunnels under the East River, and one shorter Empire Tunnel under the West Side of Manhattan. Each under-river tunnel is approximately 3 miles long, while the Empire Tunnel is approximately 0.3 miles long. The interlockings that control the station complex are designated 'A', 'C', 'JO', and 'KN'. On the west side of the station, 'A' and 'KN' interlockings route trains to and from the North River Tunnels, the Empire Tunnel, and the West Side Yard. On the east side, two interlockings ('C' and 'JO') route trains to and from the four East River tunnels; each interlocking connects two of the tunnel tracks to only 17 of the 21 platform tracks, as tracks 1–4 do not connect to the east.
Outside the cell, LTC4 can be converted by ubiquitous enzymes to form successively LTD4 and LTE4, which retain biological activity. The cysteinyl-leukotrienes act at their cell-surface receptors CysLT1 and CysLT2 on target cells to contract bronchial and vascular smooth muscle, to increase permeability of small blood vessels, to enhance secretion of mucus in the airway and gut, and to recruit leukocytes to sites of inflammation. Both LTB4 and the cysteinyl-leukotrienes (LTC4, LTD4, LTE4) are partly degraded in local tissues, and ultimately become inactive metabolites in the liver.
Sources: en.wikipedia.org
Antibody responses elicited by DNA vaccinations are influenced by multiple variables, including antigen type; antigen location (i.e. intracellular vs. secreted); number, frequency and immunization dose; site and method of antigen delivery.
== Selected publications == Araujo JV, Davidenko N, Danner M, Cameron RE, Best SM: Novel Porous scaffolds of pH Responsive Chitosan/Carrageenan-based Polyelectrolyte Complexes for Tissue Engineering. J Biomed Mater Res A. 2014 Feb 14. Pawelec KM, Husmann A, Best SM, Cameron RE: Understanding anisotropy and architecture in ice-templated biopolymer scaffolds. Mater Sci Eng C Mater Biol Appl. 2014 Apr 1;37:141-7. Pawelec KM, Husmann A, Best SM, Cameron RE: A design protocol for tailoring ice-templated scaffold structure. J R Soc Interface. 2014 Jan 8;11(92):20130958. Shepherd JH, Ghose S, Kew SJ, Moavenian A, Best SM, Cameron RE: Effect of fiber crosslinking on collagen-fiber reinforced collagen-chondroitin-6-sulfate materials for regenerating load-bearing soft tissues. J Biomed Mater Res A. 2013 Jan;101(1):176-84. Kew SJ, Gwynne JH, Enea D, Brookes R, Rushton N, Best SM, Cameron RE: Synthetic collagen fascicles for the regeneration of tendon tissue. Acta Biomater. 2012 Oct;8(10):3723-31. Grover CN, Gwynne JH, Pugh N, Hamaia S, Farndale RW, Best SM, Cameron RE: Crosslinking and composition influence the surface properties, mechanical stiffness and cell reactivity of collagen-based films. Acta Biomater. 2012 Aug;8(8):3080-90. Grover CN, Farndale RW, Best SM, Cameron RE: The interplay between physical and chemical properties of protein films affects their bioactivity. J Biomed Mater Res A. 2012 Sep;100(9):2401-11.
=== Generic names === Nefazodone is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while néfazodone is its DCFTooltip Dénomination Commune Française and nefazodone hydrochloride is its USANTooltip United States Adopted Name and USPTooltip United States Pharmacopeia.
==== Breastfeeding ==== There is no information regarding the excretion of pentamidine in breast milk, but since the adverse effects on breastfed infants are unknown currently, it is recommended by the manufacturer for the infant to not be breastfed or for the mother to stop the drug. Risks versus benefits for the mother should be considered when making this decision.
== Common Bioconjugation Reactions == Synthesis of bioconjugates involves a variety of challenges, ranging from the simple and nonspecific use of a fluorescent dye marker to the complex design of antibody drug conjugates. Various bioconjugation reactions have been developed to chemically modify proteins. Common types of bioconjugation reactions on proteins are coupling to lysine, cysteine, and tyrosine amino acid residues, as well as modification of tryptophan residues and of the N- and C- terminus. However, these reactions often lack chemoselectivity and efficiency, because they depend on the presence of native amino acids, which are present in large quantities that hinder selectivity. There is an increasing need for chemical strategies that can effectively attach synthetic molecules site specifically to proteins. One strategy is to first install a unique functional group onto a protein, and then a bioorthogonal reaction is used to couple a biomolecule with this unique functional group. The bioorthogonal reactions targeting non-native functional groups are widely used in bioconjugation chemistry. Some important reactions are modification of ketone and aldehydes, Staudinger ligation with organic azides, copper-catalyzed Huisgen cycloaddition of azides, and strain promoted Huisgen cycloaddition of azides. Bioconjugation reactions would ideally possess the criteria of easy access to the components for reaction, high yield, high rate constant, wide tolerance of reaction conditions, and applicability in diverse contexts.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。